Onko Bcg 100

Live BCG Bacilli (Bacillus Calmette‑Guerin) Brazil‑I, the active ingredient in Onko Bcg 100, is a biological vaccine presented as a live bacterial preparation for intravesical use. It is employed in bladder‑cancer immunotherapy to stimulate a local immune response that helps reduce tumour recurrence. GNH USA supplies Onko Bcg 100 as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Onko Bcg 100 as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Onko Bcg 100 is a live‑attenuated mycobacterial vaccine used in the management of uro‑urological malignancies. It is applied as part of intravesical therapy for bladder cancer.

- Non‑muscle‑invasive bladder cancer: reduces recurrence and progression after transurethral resection. - Carcinoma in situ of the bladder: induces tumour regression through immune activation. - High‑risk bladder tumours: provides additional disease‑free survival when combined with standard resection. - BCG‑refractory disease (selected cases): may be used in clinical trials or compassionate use protocols. - Maintenance therapy: prolongs the benefit of induction therapy in eligible patients. - Adjunct to intravesical chemotherapy: enhances overall response rates in combination regimens.

Adverse reactions are primarily local and systemic immune‑mediated events.

Common Side Effects: - Cystitis‑like symptoms: dysuria, urgency, frequency. - Low‑grade fever or chills. - Hematuria or mild bladder irritation. - Fatigue or malaise. - Transient flu‑like syndrome.

Serious or Rare Side Effects: - BCG‑induced sepsis or disseminated infection. - Severe allergic reaction (anaphylaxis). - Persistent high‑grade fever. - Organ‑specific granulomatous inflammation (e.g., hepatitis, pneumonitis). - Life‑threatening bladder contracture. - Autoimmune phenomena (e.g., vasculitis).

Before initiating therapy, evaluate patient suitability and monitor for complications.

- Contraindication: active tuberculosis or immunosuppression: avoid use due to infection risk. - Prior BCG exposure: assess for hypersensitivity reactions. - Recent urinary surgery: postpone treatment until healing is complete. - Hematuria of unknown origin: investigate before instillation. - Pregnancy or lactation: defer treatment; discuss risks with obstetric specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

BCG therapy can be influenced by concurrent medications and clinical conditions.

Major Interactions (Avoid): - Systemic immunosuppressants (e.g., high‑dose steroids, azathioprine): may diminish vaccine efficacy and increase infection risk. - Live‑virus vaccines administered within 4 weeks: risk of compounded infection.

Moderate Interactions (Monitor Closely): - Intravesical chemotherapy agents (e.g., mitomycin C): schedule to avoid overlapping toxicity. - Anticoagulants: monitor for haematuria. - Antifungal azoles (e.g., fluconazole): may alter immune response. - Cytokine‑modulating drugs (e.g., interferon‑α): assess additive immune activation.